# US 12,006,373 B1 · Identification and evaluation of novel peptide ligands specific to human CD3 epsilon

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,373 B1
- Document ID: US12006373B1
- Status: Granted
- Kind: B1
- Application number: 17/349,825
- Filed: 2021-06-16
- Granted: 2024-06-11
- Earliest claimed: 2020-06-16
- Assignees: Board of Trustees of the University of Alabama, for and on behalf of the University of Alabama in Huntsville
- Applicants: Board of Trustees of the University of Alabama, for and on behalf of the University of Alabama in Huntsville
- Inventors: Kyung Ho Roh; Armin Ahmadi
- Web page: https://patentgrep.com/patent/US12006373B1

## CPC

- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- C07K 5/1008: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- A61K 49/1866: {the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid}
- C07K 7/06: having 5 to 11 amino acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure is directed to anti-CD3ε peptides, compounds, and methods of using same. A biopanning technique was used to identify several phage clones displaying unique anti-CD3ε peptide sequences. The anti-CD3ε peptide sequences bind to human CD3ε on T cells, allowing the identification, labeling, and delivery of cargo to these T cells. Applications for the disclosed peptides include the labeling of T cells with magnetic particles for MRI detection and targeting of T cells with cargo-laden anti-CD3ε peptides for immunotherapy. Further still, incubation of T cells with anti-CD3ε peptides may result in the activation and increase production of T cells, which may in turn be harvested for applications such as CAR-T therapy.

## Claims

### Claim 1

A ligand for binding human cluster of differentiation 3 epsilon (CD3ε) represented by SEQ ID NO: 13.

### Claim 2

A ligand for binding human cluster of differentiation 3 epsilon (CD3ε) having the formula: SEQ ID NO:31-PEG6-lysine-biotin.

### Claim 3

A ligand for binding human cluster of differentiation 3 epsilon (CD3ε) having the formula: SEQ ID NO: 32-maleimide-PEG2-biotin.

### Claim 4

A ligand for binding human cluster of differentiation 3 epsilon (CD3ε) represented by SEQ ID NO: 13 and coupled to a labeling molecule by an attachment group of the ligand.

### Claim 5 (depends on 4)

The ligand of claim 4, wherein the labeling molecule is a fluorescent label, enzyme label, chromogenic label, luminescence label, radiation label, magnetic label, metal complex, metal, or colloidal gold.